Table III.

Association of the circRNA signature with clinicopathological characteristics in patients with pituitary adenoma.

	Training group			Test group			Entire group
Variables	Low risk	High risk	P-value	Low risk	High risk	P-value	Low risk	High risk	P-value
Sex			0.62			>0.99			0.73
Female	11	8		10	10		21	18
Male	8	10		8	8		16	18
Age, years			0.41			0.09			0.05
≤55	8	11		7	13		15	24
>55	11	7		11	5		22	12
Vision and visual field disorders			>0.99			0.05			0.13
Yes	13	13		11	17		24	30
No	6	5		7	1		13	6
Headache			0.03			0.74			0.29
Yes	13	5		8	10		21	15
No	6	13		10	8		16	21
Hypogonadism			>0.99			0.30			0.34
Yes	1	1		2	5		3	6
No	18	17		15	13		33	30
Knosp classification			0.49			0.10			0.93
I	2	4		4	1		6	5
II	6	3		2	7		8	10
III	5	3		3	5		8	8
IV	6	8		9	5		15	13
Hardy classification			0.52			0.43			0.27
II	6	9		10	13		16	22
III	4	3		3	3		7	6
IV	9	6		5	2		14	8
Pathological type			0.48			0.47			0.49
Gonadotroph	4	8		4	5		8	13
Mult	2	2		1	0		3	2
Null cell	13	8		13	12		26	20
Silent GH				0	1		0	1
Invasion			>0.99			>0.99			0.93
Yes	13	12		12	11		25	23
No	6	6		6	7		12	13

circRNA, circular RNA; Mult, Clinical non-functioning pituitary adenomas with multiple hormones positive immunostaining; GH, growth hormones.